Merck's Guidance Cut Is Accounting Noise - the Underlying Business Is Running Stronger

Merck slashed its 2026 profit guidance today. The new adjusted EPS range is $2.66 to $2.76, down from the $5.04 to $5.16 it gave before. The stock dropped nearly 2 percent on the headline.

The problem is the headline is measuring the wrong thing. The cut doesn't reflect a weaker business. It reflects Merck's decision to fold two non-cash acquisition charges into its non-GAAP guidance for the first time. Strip those out and the underlying earnings power is roughly double the new headline number.

Here's what the market is missing.

The charges

The revised guidance absorbs two items that were previously excluded from the adjusted earnings range. The first is a $5.7 billion, or $2.31 per share, charge tied to the Terns Pharmaceuticals acquisition Merck closed in May at $6.7 billion. Merck accounts for the deal as an asset acquisition, which means the purchase price hits R&D expense immediately rather than being capitalized on the balance sheet and amortized over time. It's an accounting treatment, not a cash payment.

The second is a $9 billion, or $3.62 per share, charge related to the Cidara Therapeutics acquisition completed in January. That deal brought CD388, a Phase 3 antiviral agent, into Merck's portfolio.

Both charges are one-time write-offs for in-development pipeline assets. They don't reduce free cash flow. They don't change the operating business. But they're now sitting inside the adjusted EPS range where investors naturally read them as earnings power.

The previous guidance of $5.04 to $5.16 excluded both. The new guidance of $2.66 to $2.76 includes both. Add back the $5.93 per share in charges and the underlying earnings power sits at roughly $8.59 to $8.69 per share. That's nearly 70 percent higher than the original guidance range. The business isn't worse - it's materially better, and the headline masks that entirely.

The operating proof

This is where the inflection lives. Merck's second-quarter revenue came in at $16.61 billion, a 5 percent year-over-year increase that beat analyst estimates of $16.37 billion. Keytruda - still the company's engine - generated $8.4 billion in the quarter, up 5 percent.

The more important number inside Keytruda is the $463 million from Qlex, the subcutaneous (injectable) version approved last year. Qlex matters because Keytruda's core U.S. patent expires in December 2028. Merck is shifting patients to Qlex ahead of the cliff, building clinical inertia and a formulation patent that extends protection beyond the core molecule date. That's not a distraction from the patent problem - it's the strategy for it.

Beyond Keytruda, the new product slate is accelerating fast. Winrevair, a treatment for pulmonary arterial hypertension, pulled in $588 million in the quarter, up 75 percent. The pneumococcal vaccine Capvaxive generated $184 million, up 42 percent. The animal health business posted $1.78 billion, above estimates. These aren't pipeline promises. They're revenue.

Management also raised the full-year revenue guidance to $66.3 billion to $67.3 billion, up from the prior ceiling of $67 billion. The topline story is improving, not breaking.

Free cash flow doesn't care about accounting

Free cash flow over the trailing twelve months is $14.12 billion, with an FCF margin of 21.5 percent. That's down 17 percent year-over-year, partly from higher capital expenditure as the company funds integration and launches. But the acquisition charges don't touch this number - they're non-cash. The cash conversion engine is still running.

On a $315.6 billion market cap, that $14.12 billion in free cash flow is a 4.5 percent yield. For a company with 24 consecutive years of dividend increases and a current dividend yield of 2.6 percent, the cash buffer is thick. The payout ratio at 92.5 percent of trailing earnings looks stretched only because the earnings denominator is depressed by the charges. Against free cash flow, the dividend is fully covered.

Why the market is still pricing the old story

The stock trades at 16.6 times forward earnings and 20.1 times EV/EBITDA. Those aren't cheap multiples. But the forward earnings multiple is built on a reported EPS base that includes the churn of two massive acquisition write-offs. A forward P/E of 16.6 on a temporarily depressed earnings base is not the same as a 16.6 multiple on a sustainable one.

AInvest's aggregate signal still labels Merck a Buy, with a composite analysis rating of 2.51. But that signal is reactive - it hasn't caught up to the earnings power gap the charges created. The market is anchoring to the $2.66-to-$2.76 headline and calling it full-year guidance. Once investors re-anchor to the $8.60-plus underlying run rate, the rerating is mechanical.

The bridge

Simple forward multiples do the work here. No DCF model needed - those are the illusion of control when you're trying to price pipeline options two years out.

If 2027 earnings return to the $8.50-to-$8.70 range - assuming the acquisition charges don't recur and Keytruda holds its current trajectory - a multiple of 16.5 to 17.0x prices Merck at $140 to $148. The midpoint is roughly $144.

That's a $144 target over the next 12 months, implying about 12 percent upside from today's $127.77. The timeframe is 12 months because that's how long it takes the market to stop looking at the charge-inflated 2026 guidance and start pricing the normalized 2027 run rate. The Q1 2027 report, which will be free of both acquisition charges, is the moment that happens.

The tripwire

The thesis breaks if Keytruda growth stalls or turns negative in consecutive quarters. Keytruda still represents roughly half of Merck's revenue. If the 5 percent growth rate collapses to flat or below, the Qlex transition is failing and the post-2028 outlook worsens materially.

A second tripwire is free cash flow falling below $12 billion on a trailing basis. The 21.5 percent FCF margin is the hard proof that the business can absorb acquisition spending without breaking. If that margin compresses sharply, the cash coverage for the dividend and reinvestment gets thinner.

Discipline over ego. If either of those breaks, cut. If neither does, the setup keeps getting cleaner as the charges fade from the tape and the underlying numbers speak.

Scorecard

• Thesis: Merck's underlying 2026 earnings power is roughly $8.60 per share, nearly double the $2.66-to-$2.76 headline guidance that bakes in one-time, non-cash acquisition charges.
• Target: $144 over 12 months, based on 16.5-to-17.0x forward multiples on a normalized $8.50-to-$8.70 earnings base.
• Key proof point: Q1 2027 earnings, which will be free of both the Terns and Cidara charges and show the true run rate.
• Tripwire: Keytruda growth flat or negative for two consecutive quarters, or trailing FCF falling below $12 billion.